Book Value: A Complete Guide for Investors in 2025

The book value (BV) remains a key concept in accounting and financial analysis. It reflects the real value of an asset after deducting accumulated depreciation and impairments over time. Discover how book value can guide your investment decisions in 2025 through a practical and fully up-to-date approach to modern accounting methodologies.

Introduction to Book Value

The book value is at the heart of evaluating a company's financial health. Unlike a simple valuation estimate, it takes into account all accounting changes affecting each asset listed on the balance sheet. Thus, book value allows for a precise understanding of the "true" value of an asset as it can be used or sold at any given moment.

Definition and Importance

Book value is calculated by subtracting the cumulative amount of depreciation and impairments from the acquisition cost of an asset. For example, consider equipment purchased for 100,000 € and depreciated linearly over ten years. After three years, the total depreciation is 30,000 € (10,000 € per year for three years). If the asset has also suffered an exceptional impairment of 2,000 €, the book value at the end of the third year is: 100,000 € - 30,000 € - 2,000 € = 68,000 €.

The relevance of book value is recognized:

  • It provides management with information about the true state of fixed assets.
  • It forms the basis of calculation for any potential resale, transfer, or disposal of an asset.
  • It enables the tracking of sound accounting management to ensure the sincerity and accuracy of financial statements.
  • It facilitates an objective evaluation during the takeover or merger of companies.

How to Calculate Book Value?

The universal formula for calculating book value is:

BV = Acquisition Cost - Accumulated Depreciation - Accumulated Impairments

Where:

  • Acquisition Cost: the initial purchase price of the asset, including incidental costs (transport, installation, taxes, commissions, etc.)
  • Depreciation: the total losses in value "planned," spread over the theoretical useful life of the asset
  • Impairments: losses in value noted periodically due to a disaster or rapid depreciation (technological, market, etc.)

Numerical Example

Consider a company that purchases a machine for 50,000 €, depreciated over five years. Three years later, the accumulated depreciation is 30,000 €. An impairment of 5,000 € was recorded due to the arrival of a new model. The book value of the machine is: 50,000 € - 30,000 € - 5,000 € = 15,000 €.

Current Context: Up-to-Date Data on ValiRx plc (November 2025)

In light of stock market fluctuations and the volatility of the biotechnology sector, it is essential to consult recent, dated, and accurate data to evaluate a stock.

Presentation of ValiRx plc (VAL.L): Data from November 11, 2025

  • Market Capitalization : approximately £6.1 million, or about €7.06 million (GBP/EUR rate 1.155)
  • Price per Share : 0.2365 GBP, or approximately 0.273 euro
  • Industry Sector : Health
  • Industry : Biotechnology
  • Beta : 0.36
  • P/E Ratio : not available (loss-making company)
  • Dividend : no dividend distributed since going public
  • Data Update Date : November 11, 2025

These figures illustrate the necessity of relying on dated numbers, especially when dealing with small market capitalizations trading on volatile markets like the AIM (Alternative Investment Market).

The NCAV of ValiRx plc: where to find the exact information?

The NCAV of a listed company typically corresponds to its consolidated equity, or the net asset value per share (often referred to as "book value per share"). This data is found in the annual or semi-annual financial statements. For ValiRx plc, as of June 30, 2025 (the last published statement before November 11, 2025), the consolidated equity was in negative territory, which is common for a young biotech in a development phase with recurring net losses.

Thus, the NCAV per share of ValiRx plc is currently negative, which explains the absence of a meaningful P/B (price/book value) ratio. This imposes great caution in analysis, as the market value (stock price) does not reflect the book value recorded in the balance sheet but rather the valuation of future prospects in a sector where intangibles (patents, pipeline, etc.) are paramount.

In-depth Analysis of Net Current Asset Value

Mastering the NCAV means understanding the very structure of the tangible net worth of an enterprise. Its calculation allows for adjusting the value of assets after taking into account usage, depreciation, or exceptional circumstances that have altered the original value.

Main Components of Net Current Asset Value

  • Gross Value : Purchase price of the asset, including incidental costs. This value forms the starting point for the calculation.
  • Cumulative Depreciation : Corresponds to the allocation of gross value over the estimated useful life of the asset. Example: an office building depreciated over 40 years will see its net value decrease by 2.5% each year.
  • Recorded Write-downs : If the value of the asset drops persistently due to an unfavorable event (disaster, sudden obsolescence...), a provision must be recorded to reflect a realistic view of the asset's value.

Industry-specific peculiarities of NCAV

In sectors like biotechnology or tech, intangible assets (patents, licenses) often constitute the bulk of the assets shown on the balance sheet. The Net Asset Value (NAV) is generally low or negative here, as innovation requires significant investments without any guarantee of quick profitability. This phenomenon should guide the interpretation of the NAV: in these sectors, it is mainly the capacity for innovation, the project pipeline, and intellectual property protection that create true value – not just the NAV.

Practical Example: NAV and Financial Analysis of ValiRx plc

As a case study, let's illustrate the NAV with ValiRx plc, a biotech listed on AIM.

  • Market Capitalization: €7.06 million
  • Price per Share: €0.273
  • Industry: Health
  • Sub-industry: Biotechnology
  • Beta: 0.36 (low correlation to the overall market)
  • P/E Ratio: n.a. (recurring deficit)
  • Dividend: None

Key Points for Investors:

  • The NAV of ValiRx plc as of June 30, 2025 is negative, due to accumulated losses (negative equity). This does not prevent the stock from trading on the market, as valuation primarily incorporates the potential for innovation and speculation on the development pipeline of products.
  • This situation is common in early-stage biotechs: they have no profits, no positive NAV, no dividends, but high volatility/hopes for valuation based on technological advancements.
  • To be thorough, the investor should compare the NAV to the "market capitalization" and analyze the price-to-book ratio (P/B), which is nonexistent here due to negative equity.

Comparison of NAV vs Market Value

It is essential to clearly distinguish between book value and market value. The NAV is based on the depreciated value recorded on the balance sheet, whereas market value reflects the collective perception of the company's potential (growth, innovations, market share gains, expected profitability...). For ValiRx plc, the ability to attract new financing or achieve major medical breakthroughs explains its market survival despite a negative NAV.

Investment Strategies Based on Book Value

The NAV constitutes a pillar of asset analysis, particularly useful in "value investing" approaches where investors seek undervalued listed companies relative to their real book value. However, not all situations lend themselves to this type of evaluation, especially in technology or innovative sectors.

Why Does NAV Matter to Investors?

  • Measure the strength of the asset base : A high NCA is often perceived as an indicator of robustness in industrial or real estate sectors. It signals the ability to cope with unforeseen events or to partially self-finance through the sale of assets.
  • Identify undervalued companies : If the overall NCA is significantly higher than the market capitalization, it may represent a buying opportunity (subject to verifying the quality, liquidity, and actual accessibility of the assets).
  • Anticipate resale value : For a business acquisition or the sale of an asset, the NCA serves as a basis for negotiation to assess the fair transaction price.

Limits and precautions: NCA is not everything

It is important to note that the NCA does not always reflect recent economic realities: it does not take into account current market values or the rapid potential evolution of the sector (increase or collapse in demand, technological progress, etc.). Sometimes, heavily depreciated assets may still have significant market value, or conversely, may have no real commercial value.

Optimize Your Strategy with Net Asset Value

In a world where volatility is the norm and innovation constantly redefines the value of listed companies, investors should adopt a rigorous and holistic approach.

  • In-depth fundamental analysis : Systematically review annual and semi-annual reports, particularly complete financial statements which specify the total and per share net asset value.
  • Portfolio diversification : Avoid concentrating your capital on a single technology or biotech stock. Diversification remains the indispensable ally against uncertainties inherent to these emerging markets.
  • Continuous monitoring of key indicators : Pay attention to the evolution of the NCA over official communications and the sectoral context (regulations, medical innovations, etc.).
  • Watchfulness regarding the liquidity of assets : A high NCA is less relevant if underlying assets are difficult to sell or non-strategic.
  • Study of sector potential : In biotechnology, neither the NCA nor past profitability dictates the potential of the stock, but rather the portfolio of patents, the advancement stage of molecules, and the possibility of signing strategic partnerships.

Avoiding errors in using the NCA

  • Taking the NCA in isolation without considering the real quality of the assets or their short/medium-term valuation potential.
  • Ignoring the composition of shareholders' equity, which could be "inflated" by non-productive or hard-to-value assets (obsolete brands, goodwill outside the market...).
  • Confusing the NCA on the balance sheet with the actual resale value of a company or an asset under normal market conditions.

Practical zoom: Valuation and decision-making

When faced with a company like ValiRx plc showing a negative Net Asset Value (NAV) and an insignificant Price-to-Earnings (P/E) ratio, the experienced investor will prioritize a thorough qualitative analysis (intellectual property, R&D strategy, clinical trial schedule...) while keeping in mind the risk of dilution of equity during future capital raises.

In large industrial companies or real estate, the NAV often helps identify a market discount. In tech and healthcare, it plays a lesser role but remains a useful indicator for comparing book value and market valuation.

Conclusion: The Net Asset Value, an Indispensable Foundation but to Be Used with Discernment

The Net Asset Value is an indispensable tool for assessing the financial solidity of a company. Its definition, seemingly simple, actually carries great subtlety in practice: if the NAV sheds light on the robustness of the balance sheet, it must always be supplemented by an evaluation of market potential, competitive environment, and sector dynamics.

For the modern investor, the NAV supports other indicators—margin, revenue growth, leverage, cash flow—to build a solid and multidimensional analysis. Thus, whether you are looking to invest in traditional industries or innovative sectors such as biotech, keeping an eye on the NAV will help you better understand the asset base of the company and anticipate its ability to rebound during financial shocks. However, it should always be interpreted within a broader context, integrating the company's strategy, outlook, and the quality of its assets.

In 2025, markets demand rigor and discernment: mastering the Net Asset Value will take you a decisive step further in understanding the true value of listed companies and making long-term investment choices.